A decade of immune-checkpoint inhibitors in cancer therapy

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100

Cellular immunotherapy for medulloblastoma

Schakelaar, M. Y., Monnikhof, M., Crnko, S., Pijnappel, E. W., Meeldijk, J., ten Broeke, T., & Bovenschen, N. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac236 · Cited by 28

Differential expansion of T peripheral helper cells in early rheumatoid arthritis and osteoarthritis synovium

Murray‐Brown, W., Guo, Y., Small, A., Lowe, K., Weedon, H., Smith, M., Lester, S. E., Proudman, S., Rao, N. L., Hao, L., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002563 · Cited by 26

Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion

Salnikov, M. Y., Prusinkiewicz, M. A., Lin, S., Ghasemi, F., Cecchini, M. J., & Mymryk, J. S. (2023) · Viruses · doi:10.3390/v15010176 · Cited by 25

Tumour microenvironment in pheochromocytoma and paraganglioma

Martinelli, S., Amore, F., Canu, L., Maggi, M., & Rapizzi, E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137456 · Cited by 26

Therapeutic targeting of the pituitary tumor microenvironment

Ilie, M. D., Alcubierre, D. D., Carretti, A. L., Jouanneau, E., & Raverot, G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108506 · Cited by 25

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D

Park, J., Lee, J. B., Lim, M. C., Lim, M. C., Kim, B., Kim, J., Choi, C. H., Kim, H. S., Park, S. Y., & Lee, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007444 · Cited by 25

Enhanced cancer immunotherapy through synergistic ferroptosis and immune checkpoint blockade using cell membrane-coated nanoparticles

Mu, Y., Fan, Y., He, L., Hu, N., Han, X., Guan, X., & Zheng, Z. (2023) · Cancer Nanotechnology · doi:10.1186/s12645-023-00234-2 · Cited by 25

Recent advancements of hydrogels in immunotherapy: Breast cancer treatment

Mondal, J., Chakraborty, K., Bunggulawa, E. J., An, J. M., Revuri, V., Nurunnabi, M., & Lee, Y.-K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.003 · Cited by 25

Eczematous Drug Eruptions

Blum, A. E., & Burgin, S. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00586-8 · Cited by 24

A novel role for an old target: CD45 for breast cancer immunotherapy

Raiter, A., Zlotnik, O., Lipovetsky, J., Mugami, S., Dar, S., Lubin, I., Sharon, E., Cohen, C. J., & Yerushalmi, R. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929725 · Cited by 25

Systems biology informed neural networks (SBINN) predict response and novel combinations for PD-1 checkpoint blockade

Przedborski, M., Smalley, M., Thiyagarajan, S., Goldman, A. J., & Kohandel, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02393-7 · Cited by 25

At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention

Tundo, G. R., Sbardella, D., Oddone, F., Kudriaeva, A. A., Lacal, P. M., Belogurov, A. A., Graziani, G., & Marini, S. (2021) · Cancers · doi:10.3390/cancers13194852 · Cited by 25

Fucoidan Independently Enhances Activity in Human Immune Cells and Has a Cytostatic Effect on Prostate Cancer Cells in the Presence of Nivolumab

Park, A. Y., Nafia, I., Stringer, D. N., Karpiniec, S. S., & Fitton, J. H. (2021) · Marine Drugs · doi:10.3390/md20010012 · Cited by 25

A size/charge/targeting changeable nano-booster to realize synergistic photodynamic-immunotherapy with high safety

Zang, J., He, R., Liu, Y., Su, R., Zhao, Y., Zheng, X. W., Liu, Y., Chong, G., Ruan, S., Wang, H., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.134585 · Cited by 24

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma

Brackenier, C., Kinget, L., Cappuyns, S., Verslype, C., Beuselinck, B., & Dekervel, J. (2023) · Cancers · doi:10.3390/cancers15020348 · Cited by 29

Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives

Maselli, F. M., Giuliani, F., Laface, C., Perrone, M., Melaccio, A., Santis, P. D., Santoro, A. N., Guarini, C., Iaia, M. L., & Fedele, P. (2023) · Current Oncology · doi:10.3390/curroncol30060432 · Cited by 24

Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis

Weiss, L., Weiden, J., Dölen, Y., Grad, E. M., van Dinther, E. A. W., Schluck, M., Eggermont, L. J., van Mierlo, G., Gileadi, U., Bartoló‐Ibars, A., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c11884 · Cited by 24

Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy

Morel, D., Robert, C., Nikos Paragios, A., Grégoire, V., & Deutsch, É. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3632 · Cited by 29

Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy

Hashemi, M., Khosroshahi, E. M., Tanha, M., Khoushab, S., Bizhanpour, A., Azizi, F., Mohammadzadeh, M., Matinahmadi, A., Koohpar, Z. K., Asadi, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37376 · Cited by 25

Potential of natural products and gut microbiome in tumor immunotherapy

Cao, L., Wang, X., Ma, X., Xu, M., & Li, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01032-7 · Cited by 25

Epigenetic Dysregulation in Cancer: Implications for Gene Expression and DNA Repair-Associated Pathways

Rembiałkowska, N., Rekiel, K., Urbanowicz, P., Mamala, M. B., Marczuk, K. M., Wojtaszek, M., Żywica, M., Radzevičiūtė-Valčiukė, E., Novickij, V., & Kulbacka, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136531 · Cited by 34

Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women

Martelli, V., Latocca, M. M., Ruelle, T., Perachino, M., Arecco, L., Beshiri, K., Razeti, M. G., Tagliamento, M., Cosso, M., Fregatti, P., et al. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s274283 · Cited by 23

Senescence and Aging: Does It Impact Cancer Immunotherapies?

Maggiorani, D., & Beausejour, C. M. (2021) · Cells · doi:10.3390/cells10071568 · Cited by 25

Anticancer natural products targeting immune checkpoint protein network

Chun, K., Kim, D., Raut, P. K., & Surh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.006 · Cited by 24

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives

Ciardiello, D., Maiorano, B. A., Parente, P., Rodriquenz, M. G., Latiano, T. P., Chiarazzo, C., Pazienza, V., Guerrera, L. P., Amoruso, B., Normanno, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020820 · Cited by 23

The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF‐β receptor plus dual checkpoint inhibition maintains antitumor immune cells

Rana, M., Kansal, R. G., Chaib, M., Teng, B., Morrrison, M., Hayes, D. N., Stanfill, A. G., Shibata, D., Carson, J. A., Makowski, L., et al. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23401 · Cited by 24

Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy

McCrae, K. R., Swaidani, S., Diaz-Montero, C. M., & Khorana, A. A. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.01.006 · Cited by 23

Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer

Sokač, M., Ahrenfeldt, J., Litchfield, K., Watkins, T. B. K., Knudsen, M., Dyrskjøt, L., Jakobsen, M. R., & Birkbak, N. J. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0047 · Cited by 21

Multimodal Therapies against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches toward Ultimate Nanomedicine Treatments

Conte, M., & Cauda, V. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200079 · Cited by 27

Bojungikki-Tang Improves Response to PD-L1 Immunotherapy by Regulating the Tumor Microenvironment in MC38 Tumor-Bearing Mice

Chun, J., Park, S., Yi, J.-M., Ha, I. J., Kang, H. N., & Jeong, M.-K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.901563 · Cited by 23

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy

Yan, C. M., Wu, D., Gan, L., Wang, J., Yang, W., & Xu, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.949745 · Cited by 22

Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis

Zhang, M., Song, J. H., Yang, H., Jin, F., & Zheng, A. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2106795 · Cited by 23

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

Kang, D., Liu, S.-P., Yuan, X., Liu, S.-X., Zhang, Z.-R., He, Z.-M., Yin, X.-D., & Mao, H.-Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05504-5 · Cited by 20

All-Rounder Liposomes in Cancer Immunotherapy: Strategies and Design Applications of Engineered Liposomal Nanomaterials

Lee, G., Choi, Y., Hong, J., Kim, J., Chae, J., Ahn, S., Ha, H.-J., Jeong, E., Lee, H., & Choi, J. H. (2024) · BioChip Journal · doi:10.1007/s13206-024-00147-1 · Cited by 26

Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions

Walmsley, C. S., Schoepflin, Z. R., Brabandt, C. D., Rangachari, D., Berwick, S., & Patell, R. D. (2024) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2024.102896 · Cited by 22

Membrane Fusion Strategy Boosts Immune Homeostasis, Mobilizing Macrophages to Eliminate Bacteria and Accelerate Skin Regeneration in Infected Burn Wound

Wang, X., Sun, X., Zeng, Y., Liu, S., Yi, Q., & Wu, Y. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202416791 · Cited by 22

Exosomal PD-L1 derived from hypoxia nasopharyngeal carcinoma cell exacerbates CD8+ T cell suppression by promoting PD-L1 upregulation in macrophages

Yuan, X., Liu, X., Jiang, D., Zheng, Z., Ma, X., Wu, S., Li, X., Lü, J., & Fu, M. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04047-7 · Cited by 24

MPC-mediated lactate production drives histone lactylation in dendritic cells to affect tumor progression and immunotherapy

Zhang, B., Xu, A., Wang, H., Yan, W., Zhang, Q., & Wang, S. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05881-9 · Cited by 27

Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets

Zheng, P., Yan, W., Ding, Y.-N., Zhang, Y., Chen, Z., Qian, J., & Ge, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02630-7 · Cited by 26

Immunotherapy – Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites

Sanghera, C., & Sanghera, R. (2019) · Cureus · doi:10.7759/cureus.5938 · Cited by 23

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Xue, L., Gao, X., Zhang, H., Tang, J., Wang, Q., Li, F., Li, X., Yu, X., Lu, Z., Huang, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08859-5 · Cited by 22

Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?

Goff, P. H., Bhakuni, R., Pulliam, T. H., Lee, J. H., Hall, E. T., & Nghiem, P. (2021) · Cancers · doi:10.3390/cancers13143415 · Cited by 23

Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials

Germani, M. M., & Moretto, R. (2021) · Cancers · doi:10.3390/cancers14010052 · Cited by 21

Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1

Grobben, Y., den Ouden, J. E., Aguado, C., van Altena, A. M., Kraneveld, A. D., & Zaman, G. J. R. (2023) · Cancers · doi:10.3390/cancers15030893 · Cited by 22

Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance

Monteleone, G., Franzè, E., Maresca, C., Colella, M., Pacifico, T., & Stolfi, C. (2023) · Cancers · doi:10.3390/cancers15030971 · Cited by 21

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation

Dumolard, L., Aspord, C., Marche, P. N., & Jílková, Z. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148111 · Cited by 22

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies

Anastasopoulou, A. N., Samarkos, M., Diamantopoulos, P. T., Vourlakou, C., Ziogas, D. C., Avramopoulos, P., Kouzis, P., Haanen, J. B. A. G., & Gogas, H. J. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad164 · Cited by 22

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis

Noori, M., Azizi, S., Mahjoubfar, A., Varaki, F. A., Fayyaz, F., Mousavian, A.-H., Bashash, D., Parizi, M. K., & Kasaeian, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181051 · Cited by 26

Cholesterol in colorectal cancer: an essential but tumorigenic precursor?

He, X., Lan, H., Jin, K., & Liu, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1276654 · Cited by 23

Evolution of the Tumor Microenvironment toward Immune-Suppressive Seclusion during Brain Metastasis of Breast Cancer: Implications for Targeted Therapy

Noh, M., Kim, S. S., Kim, Y. J., Jung, T., Jung, S., Rhee, J. H., Lee, J.-H., Lee, J. S., Cho, J.-H., Moon, K., et al. (2021) · Cancers · doi:10.3390/cancers13194895 · Cited by 22

Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties

Budimir, N., Dolina, J. S., Wei, J., Wang, X., Chen, S.-H., Santiago, P., Tu, G., Micci, L., Al-Khami, A. A., Pfister, S. X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003614 · Cited by 22

Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future

Lampe, H., Tam, L., & Hansen, A. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399802 · Cited by 21

Imaging and monitoring of granzyme B in the immune response

Li, X., Chen, G., Wu, K., Zheng, H., Tian, Z., Xu, Z. Q., Zhao, W., Weng, J., & Min, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1928 · Cited by 21

Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study

Kennedy, O. J., Ali, N. H., Lee, R. J., Monaghan, P. J., Adam, S., Cooksley, T., & Lorigan, P. C. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113949 · Cited by 22

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy

Yao, Z., Zeng, Y., Liu, C., Jin, H., Wang, H., Zhang, Y., Ding, C., Chen, G., & Wu, D. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03195-5 · Cited by 27

Targeted anti-cancer agents and risk of venous thromboembolism

Verso, M., Moik, F., Graziani, M., & Cohen, A. T. (2024) · Haematologica · doi:10.3324/haematol.2023.284778 · Cited by 21

Jun, an Oncological Foe or Friend?

Jafri, Z., Li, Y., Zhang, J., O’Meara, C. H., & Khachigian, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020555 · Cited by 22

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma

Popp, F., Capino, I., Bartels, J., Damanakis, A. I., Li, J., Datta, R. R., Löser, H., Zhao, Y., Quaas, A., Lohneis, P., et al. (2021) · Cancers · doi:10.3390/cancers13112689 · Cited by 22

Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer

Blessin, N. C., Abu-Hashem, R., Mandelkow, T., Li, W., Simon, R., Hube‐Magg, C., Möller‐Koop, C., Witt, M., Schmidt, A., Büscheck, F., et al. (2021) · Aging · doi:10.18632/aging.203113 · Cited by 21

Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?

Zorko, N. A., & Ryan, C. J. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00381-w · Cited by 21

Harnessing CD8+CD28− Regulatory T Cells as a Tool to Treat Autoimmune Disease

Ceeraz, S., Thompson, C. R., Beatson, R., & Choy, E. (2021) · Cells · doi:10.3390/cells10112973 · Cited by 21

Creation, Optimization, and Use of Semi-Synthetic Organisms that Store and Retrieve Increased Genetic Information

Romesberg, F. E. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167331 · Cited by 21

A nanoconfined loading strategy for highly efficient siRNA delivery and cancer therapy

Zhang, W., Zhang, Y., Luo, Y., Chen, S., Huang, Q., Cao, Z., Ming, L., & Yang, X. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101418 · Cited by 21

Does Inflammation Contribute to Cancer Incidence and Mortality during Aging? A Conceptual Review

Guerville, F., Bourdel‐Marchasson, I., Déchanet‐Merville, J., Pellegrin, I., Soubeyran, P., Appay, V., & Lemoine, M. (2022) · Cancers · doi:10.3390/cancers14071622 · Cited by 25

TIGIT axis: novel immune checkpoints in anti-leukemia immunity

Qiu, D., Liu, X., Wang, W., Jiang, X., Wu, X., Zheng, J., Zhou, K., Kong, X., Wu, X., & Jin, Z. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00817-0 · Cited by 21

Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications

Wong, C., Lam, T.-H., Liao, S.-Y., Lau, Y., Tse, H., & So, B. Y. F. (2023) · Biomedicines · doi:10.3390/biomedicines11010107 · Cited by 21

Engineering SIRPα cellular membrane-based nanovesicles for combination immunotherapy

Wang, M., Wang, Y., Mu, Y., Yang, F., Yang, Z., Liu, Y., Huang, L., Liu, S., Guan, X., Xie, Z., et al. (2023) · Nano Research · doi:10.1007/s12274-023-5397-4 · Cited by 21

Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis

Pham, J. P., On, L., Ardolino, L., Hurwitz, J., Salaün, H., Sim, H., & Joshua, A. M. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000900 · Cited by 22

Systemic Delivery of a STING Agonist‐Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis

Go, E., Yang, H., Park, W., Lee, S. J., Han, J., Kong, S. J., Lee, W. S., Han, D. K., Chon, H. J., & Kim, C. (2023) · Small · doi:10.1002/smll.202300544 · Cited by 21

Antineoplastic drugs inducing cardiac and vascular toxicity – An update

Barachini, S., Ghelardoni, S., Varga, Z. V., Mehanna, R. A., Guevara, M. M. M., Ferdinandy, P., & Madonna, R. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107223 · Cited by 23

Polysaccharide isolated from Grifola frondosa eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T cells responses

Li, X., Ruan, Q., Yang, W., Tian, H., Wu, N., Qadir, J., Wang, J., Hu, H., Liu, Y., Cai, M., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.85276 · Cited by 23

Tin‐Based 2D/3D Perovskite Vertical Heterojunction for High‐Performance Synaptic Phototransistors

Loi, H., Wang, T., Liu, D., Cao, J., Zhuang, J., Zhao, Z., Xu, Y., Li, G., Li, L., Zhai, T., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202422267 · Cited by 24

Cell-Surface Programmed Death Ligand-1 Expression Identifies a Sub-Population of Distal Epithelial Cells Enriched in Idiopathic Pulmonary Fibrosis

Ahmadvand, N., Carraro, G., Jones, M. R., Shalashova, I., Noori, A., Wilhelm, J., Baal, N., Khosravi, F., Chen, C., Zhang, J., et al. (2022) · Cells · doi:10.3390/cells11101593 · Cited by 22

Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium

Nakajima, M., Matsuyama, M., Kawaguchi, M., Matsumura, S., Kiwamoto, T., Matsuno, Y., Morishima, Y., Yoshida, K., SHERPA, M. T., Yazaki, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97391-4 · Cited by 20

Transforming bacterial pathogens into wonder tools in cancer immunotherapy

Senevirathne, A., Lloren, K. K. S., Aganja, R. P., Kwon, J., & Lee, J. H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.029 · Cited by 21

Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist

Willis, M. D., Schroeder, B. E., Marandino, L., Turajlic, S., & Carr, A. S. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-335998 · Cited by 24

Metabolic Messenger: growth differentiation factor 15

Breit, S. N., & Tsai, V. W.-W. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01353-3 · Cited by 23

Heat Shock Proteins in Lymphoma Immunotherapy

Albakova, Z., Mangasarova, Y., & Sapozhnikov, A. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660085 · Cited by 22

Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?

Arrichiello, G., Poliero, L., Borrelli, C., Paragliola, F., Nacca, V., Napolitano, S., Corte, C. M. D., Martini, G., & Martinelli, E. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100442 · Cited by 20

Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression

Karger, A., Nandigama, R., Stenzinger, A., Grimminger, F., Pullamsetti, S. S., Seeger, W., & Savai, R. (2021) · Cancers · doi:10.3390/cancers13164127 · Cited by 20

Accumulation of CD28null Senescent T-Cells Is Associated with Poorer Outcomes in COVID19 Patients

Coleman, M. J., Zimmerly, K. M., & Yang, X. O. (2021) · Biomolecules · doi:10.3390/biom11101425 · Cited by 20

Metabolic Modifications, Inflammation, and Cancer Immunotherapy

Zheng, S., Song, Q., & Zhang, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703681 · Cited by 19

The Dynamic Change of Immune Checkpoints and CD14+ Monocytes in Latent Tuberculosis Infection

Wang, P.-H., Wu, M., Hsu, C.-Y., Lin, S., Chang, Y., Lee, H.-S., Wei, Y., & Shu, C. (2021) · Biomedicines · doi:10.3390/biomedicines9101479 · Cited by 20

Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI

Chiara, L. D., Lugli, G., Villa, G., Raglianti, V., Husain‐Syed, F., Ravaglia, F., Romagnani, P., & Lazzeri, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052638 · Cited by 20

Immunotherapy in Sarcoma

Tellez, C. M., Leyfman, Y., D’Angelo, S. P., Wilky, B. A., & Dufresne, A. (2022) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2022.03.004 · Cited by 20

Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images

Tan, P., Huang, W., Wang, L., Deng, G., Yuan, Y., Qiu, S., Ni, D., Du, S., & Cheng, J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.978222 · Cited by 20

Predicting Transiently Expressed Protein Yields: Comparison of Transfection Methods in CHO and HEK293

Porosk, L., Nebogatova, J., Härk, H. H., Vunk, B., Arukuusk, P., Toots, U., Ustav, M., Langel, Ü., & Kurrikoff, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091949 · Cited by 20

Tumor immune checkpoints and their associated inhibitors

Gao, Z., Ling, X., Shi, C., Wang, Y., & Lin, A. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200195 · Cited by 21

A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment

Cui, Y., & Leng, C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1070777 · Cited by 21

New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas

Seong, G., & D’Angelo, S. P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1150765 · Cited by 22

The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria

Sachpekidis, C., Weru, V., Kopp-Schneider, A., Hassel, J., & Dimitrakopoulou-Strauss, A. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06243-y · Cited by 20

Treatment Decisions for Resectable Non–Small-Cell Lung Cancer: Balancing Less With More?

O’Reilly, D., Botticella, A., Barry, S. T., Cotter, S., Donington, J. S., Pechoux, C. L., & Naidoo, J. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389950 · Cited by 22

Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients

Houel, A., Foloppe, J., & Dieu‐Nosjean, M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101796 · Cited by 20

Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis

Chen, S., Huang, M., Zhang, L., Huang, Q., Wang, Y., & Yang, L. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.12.001 · Cited by 22

Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: Implication for Therapy

Nenkov, M., Shi, Y. H., Ma, Y., Gaßler, N., & Chen, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010006 · Cited by 23

An updated patent review on PD-1/PD-L1 antagonists (2022-present)

Uzar, W., Kaminska, B., Rybka, H., Skalniak, Ł., Magiera‐Mularz, K., & Kitel, R. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2368237 · Cited by 21

Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival

Smith, H., Easterling, R. S., Ma, J., Moodabagil, M., Meara, A. S., Owen, D. H., Crouser, E. D., Singha, A., & Ho, K. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107640 · Cited by 19

Immune checkpoint inhibitors and immunosuppressive tumor microenvironment: current challenges and strategies to overcome resistance

Gill, G. S., Kharb, S., Goyal, G., Das, P., Kurdia, K. C., Dhar, R., & Karmakar, S. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2504906 · Cited by 19

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies

Osborn, G., Stavraka, C., Adams, R., Sayasneh, A., Ghosh, S., Montes, A., Lacy, K. E., Kristeleit, R. S., Spicer, J. F., Josephs, D. H., et al. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab020 · Cited by 19

A B‐cell or a key player? The different roles of B‐cells and antibodies in melanoma

Rodgers, C. B., Mustard, C. J., McLean, R. T., Hutchison, S., & Pritchard, A. L. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13031 · Cited by 18

["Immune checkpoint inhibitors in oncology"].

Daëron, M., & Vivier, É. (2021) · PubMed

Meditating on Cancer Management at the Time of Immunotherapy

Lopci, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113025

Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes

Weidhaas, J. B. (2022) · Immuno Oncology Insights · doi:10.18609/ioi.2022.030

Immunotherapy for cancer

Lee, A. J. X. (2022) · Medicine · doi:10.1016/j.mpmed.2022.10.007 · Cited by 3

Immuno-oncology: A changing paradigm in cancer therapy

Abdel-Rahman, O. M. (2016) · Advances in Modern Oncology Research · doi:10.18282/amor.v2.i6.187 · Cited by 1